These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
365 related items for PubMed ID: 16627763
1. Oral chelators deferasirox and deferiprone for transfusional iron overload in thalassemia major: new data, new questions. Neufeld EJ. Blood; 2006 May 01; 107(9):3436-41. PubMed ID: 16627763 [Abstract] [Full Text] [Related]
2. Desferrioxamine mesylate for managing transfusional iron overload in people with transfusion-dependent thalassaemia. Fisher SA, Brunskill SJ, Doree C, Gooding S, Chowdhury O, Roberts DJ. Cochrane Database Syst Rev; 2013 Aug 21; 2013(8):CD004450. PubMed ID: 23963793 [Abstract] [Full Text] [Related]
6. Efficacy and safety of a novel combination of two oral chelators deferasirox/deferiprone over deferoxamine/deferiprone in severely iron overloaded young beta thalassemia major patients. Elalfy MS, Adly AM, Wali Y, Tony S, Samir A, Elhenawy YI. Eur J Haematol; 2015 Nov 21; 95(5):411-20. PubMed ID: 25600572 [Abstract] [Full Text] [Related]
7. Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Pepe A, Meloni A, Capra M, Cianciulli P, Prossomariti L, Malaventura C, Putti MC, Lippi A, Romeo MA, Bisconte MG, Filosa A, Caruso V, Quarta A, Pitrolo L, Missere M, Midiri M, Rossi G, Positano V, Lombardi M, Maggio A. Haematologica; 2011 Jan 21; 96(1):41-7. PubMed ID: 20884710 [Abstract] [Full Text] [Related]
8. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients. Balocco M, Carrara P, Pinto V, Forni GL. Am J Hematol; 2010 Jun 21; 85(6):460-1. PubMed ID: 20513129 [No Abstract] [Full Text] [Related]
11. Cost effectiveness of once-daily oral chelation therapy with deferasirox versus infusional deferoxamine in transfusion-dependent thalassaemia patients: US healthcare system perspective. Delea TE, Sofrygin O, Thomas SK, Baladi JF, Phatak PD, Coates TD. Pharmacoeconomics; 2007 Jun 21; 25(4):329-42. PubMed ID: 17402805 [Abstract] [Full Text] [Related]
12. Current status of iron overload and chelation with deferasirox. Choudhry VP, Naithani R. Indian J Pediatr; 2007 Aug 21; 74(8):759-64. PubMed ID: 17785900 [Abstract] [Full Text] [Related]
13. How I treat transfusional iron overload. Hoffbrand AV, Taher A, Cappellini MD. Blood; 2012 Nov 01; 120(18):3657-69. PubMed ID: 22919029 [Abstract] [Full Text] [Related]
14. Efficacy and safety of deferoxamine, deferasirox and deferiprone triple iron chelator combination therapy for transfusion-dependent β-thalassaemia with very high iron overload: a protocol for randomised controlled clinical trial. Premawardhena A, Perera C, Wijethilaka MN, Wanasinghe SK, Rajakaruna RHMG, Samarasinghe RANKK, Williams S, Mettananda S. BMJ Open; 2024 Feb 08; 14(2):e077342. PubMed ID: 38331857 [Abstract] [Full Text] [Related]
15. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia. Saliba AN, El Rassi F, Taher AT. Expert Rev Hematol; 2016 Feb 08; 9(2):151-68. PubMed ID: 26613264 [Abstract] [Full Text] [Related]
16. A randomized, placebo-controlled, double-blind trial of the effect of combined therapy with deferoxamine and deferiprone on myocardial iron in thalassemia major using cardiovascular magnetic resonance. Tanner MA, Galanello R, Dessi C, Smith GC, Westwood MA, Agus A, Roughton M, Assomull R, Nair SV, Walker JM, Pennell DJ. Circulation; 2007 Apr 10; 115(14):1876-84. PubMed ID: 17372174 [Abstract] [Full Text] [Related]
17. Evaluation of the efficacy and safety of deferiprone compared with deferasirox in paediatric patients with transfusion-dependent haemoglobinopathies (DEEP-2): a multicentre, randomised, open-label, non-inferiority, phase 3 trial. Maggio A, Kattamis A, Felisi M, Reggiardo G, El-Beshlawy A, Bejaoui M, Sherief L, Christou S, Cosmi C, Della Pasqua O, Del Vecchio GC, Filosa A, Cuccia L, Hassab H, Kreka M, Origa R, Putti MC, Spino M, Telfer P, Tempesta B, Vitrano A, Tsang YC, Zaka A, Tricta F, Bonifazi D, Ceci A. Lancet Haematol; 2020 Jun 10; 7(6):e469-e478. PubMed ID: 32470438 [Abstract] [Full Text] [Related]
19. [Post transfusionnal iron overload]. Rose C. Rev Prat; 2006 Dec 15; 56(19):2141-5. PubMed ID: 17416052 [Abstract] [Full Text] [Related]
20. New chelation therapies and emerging chelating drugs for the treatment of iron overload. Kontoghiorghes GJ. Expert Opin Emerg Drugs; 2006 Mar 15; 11(1):1-5. PubMed ID: 16503822 [Abstract] [Full Text] [Related] Page: [Next] [New Search]